Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Aptinyx Inc (APTX)

Aptinyx Inc (APTX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 137,269
  • Shares Outstanding, K 33,562
  • Annual Sales, $ 6,570 K
  • Annual Income, $ -53,280 K
  • 60-Month Beta 0.22
  • Price/Sales 21.19
  • Price/Cash Flow N/A
  • Price/Book 1.23

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.59
  • Number of Estimates 4
  • High Estimate -0.40
  • Low Estimate -0.80
  • Prior Year -0.42
  • Growth Rate Est. (year over year) -40.48%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.07 +34.20%
on 11/22/19
4.32 -4.63%
on 12/10/19
+0.89 (+27.55%)
since 11/08/19
3-Month
2.61 +57.85%
on 10/14/19
4.32 -4.63%
on 12/10/19
+0.17 (+4.30%)
since 09/10/19
52-Week
2.61 +57.85%
on 10/14/19
22.99 -82.08%
on 12/12/18
-16.75 (-80.26%)
since 12/10/18

Most Recent Stories

More News
Aptinyx to Present Preclinical Data Exhibiting Effects of NYX-783 in Models of PTSD and Alcohol Use Disorder at the American College of Neuropsychopharmacology's Annual Meeting

Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced a presentation highlighting...

APTX : 4.12 (+0.73%)
Aptinyx Initiates Phase 2 Study of NYX-458 in Patients with Mild Cognitive Impairment Associated with Parkinson's Disease

Phase 2 study follows NYX-458 preclinical data demonstrating reversal of cognitive deficits in non-human primate model of Parkinson's disease

APTX : 4.12 (+0.73%)
Aptinyx to Present at Upcoming Investor Conferences

Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that company management...

APTX : 4.12 (+0.73%)
Aptinyx Inc. (APTX) Reports Q3 Loss, Tops Revenue Estimates

Aptinyx Inc. (APTX) delivered earnings and revenue surprises of 4.35% and 2.86%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

APTX : 4.12 (+0.73%)
Aptinyx Reports Third Quarter 2019 Financial Results and Highlights

Initiated two Phase 2 studies of NYX-2925 in chronic pain conditions

APTX : 4.12 (+0.73%)
Aptinyx Initiates Two Phase 2 Studies of NYX-2925 in Patients with Chronic Centralized Pain Conditions

200-patient painful diabetic peripheral neuropathy study and 300-patient fibromyalgia study build on previous compelling data obtained in these indications

APTX : 4.12 (+0.73%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aptinyx Inc. - APTX

Pomerantz LLP is investigating claims on behalf of investors of Aptinyx Inc. ("Aptinyx" or the "Company") (NASDAQ: APTX). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com...

APTX : 4.12 (+0.73%)
Earnings Preview: Aptinyx Inc. (APTX) Q3 Earnings Expected to Decline

Aptinyx Inc. (APTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

APTX : 4.12 (+0.73%)
Aptinyx to Report Third Quarter 2019 Financial Results on Tuesday, November 12, 2019

Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the company will...

APTX : 4.12 (+0.73%)
EQUITY ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of Aptinyx Inc.

Levi & Korsinsky reminds investors that it has commenced an investigation of Aptinyx Inc. ("Aptinyx" or "the Company") (NASDAQ: APTX) concerning possible violations of federal securities laws.

APTX : 4.12 (+0.73%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Average short term outlook on maintaining the current direction.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Trade APTX with:

Business Summary

Aptinyx Inc. is a bio-pharmaceutical company. It focuses on discovery, development, and commercialization of novel, proprietary and synthetic small molecules for the treatment of brain and nervous system disorders. The company's product pipeline consists of NYX-2925, NYX-783 and NYX-458 which are in...

See More

Key Turning Points

2nd Resistance Point 4.49
1st Resistance Point 4.31
Last Price 4.12
1st Support Level 3.95
2nd Support Level 3.77

See More

52-Week High 22.99
Fibonacci 61.8% 15.20
Fibonacci 50% 12.80
Fibonacci 38.2% 10.40
Last Price 4.12
52-Week Low 2.61

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar